在门诊环境中绘制药物类与突然心脏骤停的关联:基于人口的探索性病例控制分析
Safoura Sheikh Rezaei1, Martina Mittlböck2, Michael Schwameis3
1Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Austria.
BMJ evidence-based medicine
|January 20, 2026
概括
在一项大型的奥地利研究中,新处方药与突然心脏骤停 (SCA) 有关. 这项研究绘制了药物风险图,确定了与增加SCA事件相关的特定类别,以指导未来的安全调查.
科学领域:
- 药物监督 药物监督 药物监督
- 流行病学 流行病学
- 心血管研究研究心血管研究
背景情况:
- 突然心脏骤停 (SCA) 构成了重大的公共卫生挑战.
- 了解新处方药的人口级风险概况对于患者安全至关重要.
研究的目的:
- 在人口层面上系统地绘制与突发心脏骤停 (SCA) 相关的药物类别.
- 为了识别新处方的药物的潜在安全信号.
主要方法:
- 在奥地利维也纳 (2013-2020年) 进行了一项基于人口的匹配病例控制研究.
- 医疗补偿和救护车服务的相关数据包括31,330人 (6,266例SCA病例,25,064例对照).
- 在SCA事件发生后4周内新处方的药物被分析使用条件逻辑回归,调整为并发症.
主要成果:
- 在322种药物类别中,57种 (23%) 显示与SCA有显著的关联.
- 八种药物类别具有明显的高风险 (OR≥10),包括oripavine衍生物 (OR 64) 和其他心脏制剂 (OR 22).
- 经常相关的药物类别包括带有β-乳糖酶抑制剂的青素 (OR 2.17),pyrazolones (OR 2.14) 和带有抗胆固醇药的腺激素 (OR 2.94).
结论:
- 许多门诊药物类与SCA相关.
- 这项研究提供了潜在药物安全信号的系统地图.
- 这些发现需要进一步进行药物流行病学调查,以严格检查因果关系和混关系.
相关概念视频
Drug Classes and Categories
3.0K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.0K
Antihypertensive Drugs: Thiazide-Class Diuretics
1.7K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.6K


